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to discuss indications, management, mechanisms of regeneration, as well as pitfalls of this novel technique.
The aim of the meeting was to make an inventory of what has been achieved and what remains unclear
in ALPPS. RESULTS: Precise knowledge of liver anatomy and its variations is paramount for success
in ALPPS. Technical modifications, mainly less invasive approaches like partial, mini- or laparoscopic
ALPPS, mostly aiming at minimizing the extensiveness of the first-stage procedure, are associated with
improved safety. In fibrotic/cirrhotic livers the degree of future liver remnant hypertrophy after ALPPS
appears some less than that in noncirrhotic. Recent data from the only prospective randomized con-
trolled trial confirmed significant higher resection rates in ALPPS with similar peri-operative morbidity
and mortality rates compared with conventional 2-stage hepatectomy including portal vein embolization.
ALPPS is effective reliably even after failure of portal vein embolization. CONCLUSIONS: Although
ALPPS is now an established 2-stage hepatectomy additional data are warranted to further refine indi-
cation and technical aspects. Long-term oncological outcome results are needed to establish the place of
ALPPS in patients with initially nonresectable liver tumors.
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Objective: Associating Liver Partition and Portal vein ligation for Staged
hepatectomy (ALPPS) has been tested in various indications and clinical
scenarios, leading to steady improvements in safety. This report presents the
current status of ALPPS.
Summary Background Data: ALPPS offers improved resectability, but
drawbacks are regularly pointed out regarding safety and oncologic benefits.
Methods: During the 12th biennial congress of the European African-Hep-
ato-Pancreato-Biliary Association (Mainz, Germany, May 23–26, 2017) an
expert meeting ‘‘10th anniversary of ALPP’’ was held to discuss indications,
management, mechanisms of regeneration, as well as pitfalls of this novel
technique. The aim of the meeting was to make an inventory of what has been
achieved and what remains unclear in ALPPS.
Results: Precise knowledge of liver anatomy and its variations is paramount
for success in ALPPS. Technical modifications, mainly less invasive
approaches like partial, mini- or laparoscopic ALPPS, mostly aiming at
minimizing the extensiveness of the first-stage procedure, are associated
with improved safety. In fibrotic/cirrhotic livers the degree of future liver
remnant hypertrophy after ALPPS appears some less than that in noncirrhotic.
Recent data from the only prospective randomized controlled trial confirmed
significant higher resection rates in ALPPS with similar peri-operative
morbidity and mortality rates compared with conventional 2-stage hepatec-
tomy including portal vein embolization. ALPPS is effective reliably even
after failure of portal vein embolization.
Conclusions: Although ALPPS is now an established 2-stage hepatectomy
additional data arewarranted to further refine indication and technical aspects.
Long-term oncological outcome results are needed to establish the place of
ALPPS in patients with initially nonresectable liver tumors.
Keywords: ALPPS, associating liver partition and portal vein ligation for
staged hepatectomy, colorectal liver metastases, portal vein embolization
(Ann Surg 2019;269:114–119)
I n autumn 2007, about 10 years ago, Prof. HJ Schlitt from Regens-burg, Germany, performed, somewhat incidentally, the first ‘‘in-
situ-split’’ procedure.1 This innovative concept rapidly spread
throughout Germany. It was introduced in the surgical world in
2011 at the congress of the European African-Hepato-Pancreato-
Biliary Association, held in Capetown, South Africa, where it
triggered tremendous curiosity. One year later, the initial experience
with 25 cases operated in 5 German centers was reported as the
inaugural study in this journal.1 In an accompanying editorial, this
procedure was quoted as ‘‘a novel concept representing one of the
most promising advances in oncological liver surgery so far.’’2 This
provocative statement subsequently triggered a vivid discussion
among the HPB community. To ease communication for future
reports the acronym ALPPS (‘‘Associating Liver Partition and Portal
vein ligation for Staged hepatectomy’’) was introduced, and subse-
quently rapidly adopted.2 Soon after, an international registry was
created to collect data on a voluntary basis frommany centers around
the world3, which currently counts more than 1000 cases.
ALPPS was tested by many groups in various indications and
clinical scenarios leading on one hand to improved resectability, but
also to the identification of significant drawbacks. Nevertheless,
ALPPS is currently considered by many as a true innovative proce-
dure, since it enables extensive liver resections well beyond the safe
resection of 70% of liver volume.4
Originally, the ALPPS procedure was designed for a right
trisectionectomy. Interestingly, a first report from the International
ALPPS Registry indicated that this approach was also applied for
standard right hepatectomy in about half of the cases; mainly in livers
with steatosis or underlying parenchymal injuries, typically related to
the use of excessive chemotherapy or, with the need for tumorectomy
or ablative surgery in the remnant liver.
From a survey sent in 2014 to surgeons participating in the
International ALPPS Registry, a high variability in indications,
patient selection, and surgical technique was documented, highlight-
ing the need for standardization. The first International Expert
meeting, held in Hamburg in 2015, produced 8 recommendations
regarding technique and indication for ALPPS5, as well as sugges-
tions for standardization for the terminology.6
The 10th anniversary of ALPPS was ‘‘celebrated’’ during the
12th biennial congress of the European African-Hepato-Pancreato-
Biliary Association (Mainz, Germany, May 23–26, 2017) at an
expert meeting to discuss indications, management, mechanisms
of regeneration, as well as pitfalls of this novel technique. The
aim of the meeting was to make an inventory of what has been
achieved and what remains unclear in ALPPS. Each expert contrib-
uted to this manuscript by providing the key features of his topic.
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How It Began? The First ‘‘In-Situ Split Liver
Resection’’
Liver resection with potential for cure is technically possible in
many cases, but often cannot be done because of a too small future liver
remnant (FLR). This scenario occurred in a 49-year-old patient with
perihilar cholangiocarcinoma (PHC) operated at Regensburg Univer-
sity, Germany, in September 2007. Right trisectionectomy was
required, but the predicted FLR seemed to be critically small. Despite
this concern, the decision for exploration was made. Intraoperatively,
the first step was to divide the left hepatic duct at the base of the round
ligament. A frozen section showed a tumor-free resection margin.
After minimal preparation in the hilum, the right portal vein was
divided followed by transection of the liver parenchyma along the
falciform ligament down to the inferior vena cava, and to the conflu-
ence of the left andmiddle hepatic veins. The right hemi-liverwas then
mobilized from the retroperitoneum and the right hepatic vein
encircled with a vessel-loop. At this point of the operation, reassess-
ment of volume and parenchymal quality of the FLR (segment II and
III) re-emerged the concern of a too small volume. The surgeon
decided to stop the procedure omitting the completion of the resection
leaving the right hemiliver in situ with preserved arterial perfusion and
preserved venous and biliary drainage. Finally, the central stump of the
left duct was suture-closed and a Roux-en-Y hepatico-jejunostomy
was performed to the left hepatic duct.
Since the patient tolerated this aborted procedure well, a com-
puted tomography (CT) scan was performed after 1 week disclosing an
almost doubling in volume of FLR. This led the surgeon to proceedwith
a second step surgery to complete, only8days after the initial surgery, the
hepatectomy. While the patient had an uneventful recovery, she devel-
oped peritoneal carcinomatosis within 6 months of surgery.
The same approach was planned and carried out with minor
modifications in 2 subsequent patients, one with colorectal liver
metastases and the other with intrahepatic cholangiocarcinoma. This
new approach originally termed ‘‘in-situ-split liver resection’’ was
adopted by a few German centers, and their inaugural experiencewas
published in 2012.1
Is Knowledge of the Anatomy Central for
Successful ALPPS?
The ALPPS concept is based on a complete portal venous
devascularization of the tumor carrying liver with preservation of the
arterial blood flow triggering tremendous hypertrophy of the con-
tralateral part of the liver. Injury to branches of the hepatic artery on
the tumor carrying liver (the future specimen) may cause necrosis
and failure of the procedure. Also, injury to biliary structures and bile
leak during the interstage phase must be avoided. Consequently,
precise anatomical knowledge is crucial. Due to the high proportion
of vasculo-bilary variants, preoperative imaging is mandatory to
assess not only the FLR, but all individual anatomical details.7
Hepatic Artery (HA)
Attention must be paid to the hilar/intrahepatic branching of the
HA. Replaced right and left HA are themost propitious arterial variants.
The HA is seldom dissected in ALPPS and the arteries are divided into
supra-glissonian intrahepatic technique at the second stage. However,
the ‘‘middle hepatic artery’’ and the branches supplying segment IVare
important in right trisectionectomy, and their preservation at stage 1 is
imperative for proper perfusion of segment IV.8
Portal Vein (PV)
PV anatomical variants are well known9,10 with most varia-
tions on the right side. Single PV branching (Types I or A according
to Cheng and Nakamura, respectively) or trifurcation (Types II or B)
versus truly abnormal configurations of the origin of the right (Type
3-4/C-D) must be recognized. Missing a PV is more likely to happen
at stage 1, when a medial right sectorial PV is overlooked. Failure of
regeneration may occur due to lack of obliteration of a PV branch
either because of large tumors on the right hilum, or an aberrant
anatomy.
Bile Duct (BD)
The bile duct should not be transected during stage 1, and the
approach to the bile ducts is extra-glissonian at stage 2, thus usually
unproblematic following correct lines of resection. However, the risk
of bile leak is more prominent at right trisectionectomy with intra-
hepatic biliary obstruction (eg, in PHC), when inappropriate umbili-
cal groove dissection can cause bile duct injury.11 A single left
hepatic duct is present in 98% of cases, but a standard left BD
anatomy, with a single segment IV BD distant from the SII-III
bifurcation is present in only 55% of cases.12 Thus, a segment IV
BD entering the BD to segment III might be injured during paren-
chymal transection resulting in bile leak. Special consideration is
needed regarding right ducts draining into the left biliary system,
particularly right posterior ducts described as Choi type 3 A, Huang
A3/Nakamura C or Couinaud D1/D2.10,13–15 In both, partial and full
ALPPS, a Glissonian pedicle will be expected and preserved in the
deeper extent of the parenchymal dissection.
Hepatic Vein (HV)
The general principle of preserving the venous outflow to the
remnant liver is respected also for ALPPS at stage 1. In right
hepatectomy, the preservation of the left main HV only, despite
all variants, is sufficient and well tolerated. In ALPPS for right
trisectionectomy, preservation of the middle HVoutflow is advised at
stage 1.12 The venous drainage of the left lateral segments is quite
constant with a common stem of the left HV.12 The rare case of a
Segment III HV draining into the middle HV needs to be considered.
This potentially risky constellation requires the preservation of the
proximal middle HV in continuity with the aberrant HV at stage 2.
Particular Surgical Consideration Regarding
Segment IV
Segment IV ischemia and bile leaks can be observed in right
trisectionectomy following injuries of segment IV HA and bile duct
at stage 1. To prevent such complications, an anatomical intra-
glissonian dissection at the umbilical groove is required, preserving
segment IV HA and respecting segment IV biliary anatomy. This
approach is preferred to a direct nonanatomical parenchymal division
into segment IV at the level of the umbilical line.
What Are the Essential Diagnostic Tools Prior to
Engage in ALPPS?
The 2 main diagnostic issues in ALPPS are the volumetric
assessment of the FLR (preferably using the standardized future liver
remnant volume (FLRV) or the ratio of FLRV and body weight
(FLRV-BWR)) and the timing of stage 2 (sufficient volume gain or
better sufficient gain of functional volume). Correlations of CT-
volumetry with liver function and postoperative outcomes are,
however, not consistent, since FLRV does not necessarily reflect
function, which might be impaired by an underlying parenchymal
damage. Of note, liver failure after ALPPS occurred in 14 and 30%
after stage 1 and 2, respectively, and 75% of the deaths after ALPPS
are related to liver failure.16 This discrepancy between volume
increase (up to 200%) and the high rate of liver failure may be
Annals of Surgery  Volume 269, Number 1, January 2019 10th Anniversary of ALPPS—Lessons Learned and quo Vadis
 2018 Wolters Kluwer Health, Inc. All rights reserved. www.annalsofsurgery.com | 115
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
attributed to a lack of maturity of the regenerating hepatocytes, and
suggests the necessity to assess liver function in addition to volume.17
Liver Function Tests
The indocyanine green (ICG) clearance test is a quantitative
liver function test, which depends on overall liver blood flow. The
test is therefore less applicable during ALPPS because of unilateral
division of the portal vein and redistribution of portal and hepatic
arterial flow. Furthermore, the ICG clearance test is a global liver
function test, which does not provide information on segmental
function.
Assessment of Volume and Function in ALPPS
Scintigraphic liver function tests, such as hepatobiliary scin-
tigraphy (HBS) using 99mTc-labeled iminodiacetic acid derivates,
have the advantage of providing quantitative and visual information
on regional hepatic function. The combination of HBS with single-
photon emission computed tomography delivers quantitative infor-
mation regarding segmental liver function, and therefore provides a
regional measure of the function of the FLR. In surgical populations
with and without compromised liver parenchyma, the FLR uptake
rate for safer liver resection was calculated to be 2.7/min/m2 or
higher, and this cut-off value has been used regardless of the quality
of the liver.18 This technique is now routinely used in several centers
in the work-up of patients eligible for major liver resection. When the
FLR uptake rate is found to be less than 1.7/min/m2, patients are
unlikely to reach sufficient FLR function after portal vein emboliza-
tion (PVE) rendering these patients upfront candidates for ALPPS.19
Sequential measurements of HBS appear also attractive to
assess the functional response to ALPPS: it was shown that as soon as
the FLR uptake rate has reached 2.7/min/m2, the second stage can be
undertaken. The use of HBS for timing of stage 2 in ALPPS was
compared with CT volumetry in 60 patients completing ALPPS in 6
centers. The results showed that often volumetry overestimated liver
function.20
What Are the Underlying Mechanisms of Liver
Growth in ALPPS?
The key feature of the ALPPS approach is the rapid volume
increase in response to stage 1. The presumed molecular pathways
behind this unprecedented liver regeneration remain unclear,
although some interesting observations are emerging. Despite the
exponentially growing number of technical and clinical studies on
ALPPS, the number of laboratory studies has remained modest
(Fig. 1). Various animal models, in mouse, rat, and swine, have
been developed mimicking ALPPS in human. Although there is no
consensus which lobe of the liver to choose as the FLR, the common
finding is that these ALPPS models exhibit accelerated regeneration
compared with conventional portal vein occlusion. The first ALPPS
model, developed in mice, revealed accelerated liver regeneration of
a very small FLR after stage 1, allowing the successful completion of
stage 2 within 48 hours of surgery.21 This model induced liver
hypertrophy superior to portal vein ligation (PVL) already 24 hours
after stage 1 (Fig. 2). The injection of ALPPS mouse plasma in mice
subjected only to PVL, that is, omitting the transection in stage 1, led
to a comparable degree of regeneration as the complete ALPPS
procedure. This simple approach suggested that circulating inflam-
matory and growth factors mediate liver regeneration in ALPPS.
Specifically, IL-6 and TNFa appeared upregulated after stage 1, with
similar observation in humans.21 Other ALPPS models in rats
disclosed analogous results with additionally upregulation of
pSTAT3, nuclear NFkBp65, and YAP.22,23
Interesting laboratory works further showed that the cell cycle
entry and progression were found to be accelerated in ALPPS
compared with PVL controls. Transcriptomic data identified Indian
hedgehog (Ihh) to be upregulated in ALPPS, as early as 4 hours after
stage 1. Functional experiments by injection of recombinant Ihh
combined with PVL mimicked the quick regeneration seen in
complete ALPPS stage 1, and neutralization of Ihh abrogated the
regeneration normally seen in ALPPS.24 These results cemented the
importance of the hedgehog pathway. Furthermore, Ihh was present
early after stage 1 in human plasma, confirming there is a clinical
relevance to this molecular pathway.24
In patients, studies aimed to elucidate many technical aspects,
mostly with the aim of reducing morbidity. For example, the search
for the minimum amount of transection necessary to induce ALPPS
showed that full versus partial transection induced comparable
increase in liver growth. Using the ALPPS mouse model, it was
found that a minimum of 50% transection was necessary to induce
the accelerated regeneration process.25
Another study was designed to determine, which components
cause the large volume increase in ALPPS—hepatocyte
FIGURE 1. Discrepancy of clinical and basic science studies on
ALPPS. While the number of clinical studies is steadily increas-
ing, experimental studies looking on the mechanism of this
accelerated regeneration process remain rare.
FIGURE 2. ALPPS-induced liver regeneration appears markedly
increased compared with PVL. Experimental data in mice show
a significantly increased FLR to BW compared with PVL and the
respective controls, transection alone and sham laparotomy
already 24hours after stage 1.21 BW indicates body weight.
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proliferation, steatosis, or edema.26 Analyzing biopsies from patients
including Ki67 and pH3 staining, steatosis, as well as water fraction,
it was found that the volume increase in ALPPS patients results from
efficient hepatocyte proliferation, rather than steatosis or edema. The
observation, however, that volume does not match full liver function
suggests that apparently cell proliferation does not lead immediately
to full maturity.17
There is still much to be investigated regarding the optimi-
zation of the ALPPS procedure and the molecular mechanisms that
drive the unprecedented liver regeneration. Accepting 1 animal
model would create a consistent platform to investigate the regener-
ation of the FLR after ALPPS, thereby creating the opportunity for
solid links to be made between basic research and clinical data. Many
questions remain open and further investigations of pathways essen-
tial to liver regeneration will lead the way to better understanding this
complex procedure, and improving clinical care.
Can Technical Modifications Improve Safety?
The current paradigm of ALPPS is represented by an inva-
sive and prolonged first surgical procedure (stage 1) followed by a
somehow shorter and less aggressive second stage.1,2 This strategy
with complete transection has been adopted by most centers as the
classical ALPPS technique. Partial transection offers comparable
FLR hypertrophy, but significantly lower morbidity, when com-
pared with total transection (38.1 vs. 88.9%; P ¼ 0.049) and near
zeromortality.27,28 Recent clinical and experimental evidence from
a multicentric study suggests that parenchymal transection in
partial ALPPS should be at least 50% to achieve equivalent
hypertrophy compared with complete transection.25 Total transec-
tion should therefore only be performed, when a tumor is too close
to the FLR boundaries to isolate the tumor and prevent margin
invasion.
When completing stage 1 procedure, it is advisable to perform
a transcystic hydraulic, air-bubble or ‘‘white’’ test (eg, use of
propofol) and sometimes cholangiography to prevent interstage bile
leaks. Bile duct ligation should never be performed, as it might cause
cholestasis, infection, and bile leaks. The identification of the
vasculo-biliary structures with vessel loops is recommended to
facilitate their identification at stage 2.29
Some authors have initially proposed to place a plastic sheet at
the liver partition site with the aim of minimizing adhesions, today
most surgeons prefer a hemostatic sheet. The resection of the tumor-
carrying liver is facilitated using vascular staplers for vascular
structures and the remaining liver parenchyma, if present. Finally,
it is also recommended to repeat a bile leak test after stage 2.
Given the existence of many technical variants described with
inconsistent and confusing names, a ‘‘consensus’’ terminology has
been recently reported.6 Some authors have replaced transection
during the 1st stage by applying a tourniquet around a parenchymal
groove of 1 cm in the future transection line (Tourniquet ALPPS).
However, the 64% morbidity and 9% mortality in their series did not
reflect a real improvement in terms of patient safety 30. Others have
proposed to replace parenchymal transection by using radiofre-
quency or microwave ablation (Radiofrequency and Microwave
ALPPS) to create a functional liver partition through a ‘‘necrotic
groove.’’ These approaches provided a similar hypertrophic profile
than the standard ALPPS, but with putatively with less complications
and mortality.31 Following the trend to less invasiveness, the ligation
of the portal venous branches to the tumor-carrying liver may also be
replaced by PVE during the interval period.32
In line with this concept, the so-called ‘‘mini-ALPPS,’’ com-
bining partial parenchymal transection and intraoperative PVE, that
is, obviating the need for the dissection of the porta hepatis, minimize
the surgical impact of first stage promoting better patient recovery
prior to the 2nd stage.33
Is Laparoscopic ALPPS Feasible and Safe?
As for open surgery, the first stage includes the exploration of
the abdominal cavity and ultrasound through a 4-trocar approach. If
necessary, nonanatomical resections can be performed in the FLR
using laparoscopic ultrasound as guidance. The portal vein is ligated
with a nonabsorbable suture followed by transection, and parenchy-
mal transection is carried from caudal to cephalad.
Stage 2 procedure can also be performed laparoscopically: the
right liver is fully mobilized off the retroperitoneum, diaphragm, and
inferior vena cava. The right Glissonian pedicle is divided with an
endostapler. Staplers are also used to transect the right and—and in
some patients—the middle hepatic veins followed by the removal of
the specimen inside a large plastic bag through a suprapubic incision.
At the University of Sa˜o Paulo, between 2011 and 2016, first
stage of ALPPS was performed in 30 patients with noncirrhotic liver,
and 28 underwent the second stage. The procedure was performed
laparoscopically without conversion in 10 patients, of whom 2
underwent ALPPS with a right-sided FLR and 1 patient had a
monosegment ALPPS. In laparoscopic ALPPS, no mortality and
no complication  grade 3 occurred, and no liver failure was
observed.34 Moreover, the hospital stay was shorter in the laparo-
scopic, when compared with open ALPPS groups (11 vs. 14 days; P
¼ 0.01).35,36 These results indicate that laparoscopic ALPPS is
feasible, and it is not inferior to the open approach.
Is the Interstage Course Central for Optimal
Outcome?
Recent results from the ALPPS registry showed that the vast
majority (93%) of deaths occur after stage 2 with posthepatectomy
liver failure being the first cause of poor outcome.16 Poststage 1
morbidity appears as a strong predictor for poststage 2 mortality.
Thus, complications during the interstage phase are determinant for
the outcome after ALPPS.
The prestage 1 risk score depicts patient age (>67 yrs) and
tumor type as independent risk factors for futile outcome. Impor-
tantly, biliary tumors with associated cholestasis represent a high-risk
entity in this score.16,37 Interstage morbidity  grade 3b complica-
tions34 and prestage 2 bilirubin and creatinine levels are associated
with higher 90-day mortality after stage 2.37
A recent analysis demonstrated that results of ALPPS have
significantly improved over the years due to patient selection,
reduced invasiveness of the ALPPS procedure due to technical
refinements, mostly aiming at a reduction of stage 1 trauma. Both
developments decrease the interstage complication rates and conse-
quently morbidity and mortality after stage 2.38
Is ALPPS in Fibrotic/Cirrhotic Livers Safely Feasible?
Surgery for hepatocellular carcinoma (HCC) in cirrhosis
represents a particular challenge. While the functional and regener-
ative capacity of a cirrhotic liver is difficult to assess preoperatively,
the use of PVE or ALPPS stage 1 is a valuable test for the
regenerative ability and presumed outcome after the completion
of the hepatectomy. Patients with liver cirrhosis additionally poorly
tolerate complications, even during a limited stage 1 procedure.
At San Camillo Forlanini in Rome, 16 ALPPS have been
performed for HCC and in 1 for HCC-ICC, including 3 ALPPS as
rescue therapy after failure of PVE or PVL. All but 1 patient were
Child A with a median MELD score of 9. In 9 cases a vascular
thrombus was removed during stage-1 to secure vascularization of
the FLR. One patient died within 90 days postoperatively.
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At The University of Hong Kong, patients with HCC are
eligible for ALPPS when the FLR volume is  30% of the estimated
standard liver volume in the presence of Child A cirrhosis, the ICG
clearance rate is< 20% at 15 minutes, the platelet count> 100109/
L, and in absence of complete right PV thrombosis (partial right PV
thrombosis is regarded as a good indication for ALPPS). Forty-two
patients underwent an ALPPS procedure, of whom 38 patients (90%)
had HCC (hepatitis B¼ 36, hepatitis C¼ 1, fatty liver¼ 1) and all of
them underwent both stage I and II operation. In the initial report
there was a volume gain of the FLR of 48.7% inducing an increment
of FLR/estimated standard liver volume ratio from 24.2 to 38.5%
over a median of 6 days.39 The 90-day mortality rate was 7.1% (n ¼
3) consistently related to liver failure. In addition to the benefit of
shorter waiting time to hepatectomy there are 2 main advantages of
ALPPS compared with PVE in fibrotic/cirrhotic livers, both related
to stage 1: first, the visual assessment of liver parenchyma quality
plus a possibility for liver biopsies to stage the degree of cirrhosis
before proceeding to hepatectomy. Second, intraoperative measure-
ment of portal hemodynamics enables better assessment of the
postoperative liver failure risk and the opportunity to apply flow
modulation, for example, splenic artery ligation if needed.
Although the degree of FLR hypertrophy in fibrotic/cirrhotic
livers appears somewhat less substantial than that in noncirrhotic,
noncholestatic livers3, the Rome and Hong Kong experience shows
that the ALPPS procedure remained an effective approach for FLR
augmentation in patients with hepatitis-related HCC.
Is Colorectal Liver Metastases the Best Indication
for ALPPS?
In Western countries, colorectal liver metastases represent the
main indications for liver surgery. Due to the pattern of metastasis
with frequent multifocal and bilateral liver involvement, various 2-
stage procedures have been developed, including ALPPS.2 The first
report of the International ALPPS Registry in 2014 revealed that
colorectal liver metastases (CRLM) was the indication in 70% of the
212 initial patients. Compared with other indications, the morbidity
and mortality after ALPPS was the lowest.3
A subsequent publication from the ALPPS registry disclosed a
mortality rate of 5% for CRLM after stage 2,16 a figure in the range of
the reported mortality after major hepatectomy.
The most recent publication of the ALPPS registry in 2016
noted a continuous drop in risk-adjusted early mortality and mor-
bidity. Centers with the most experience performing ALPPS showed
a shift in indication toward CRLM after neoadjuvant chemotherapy.
The results confirm that patients with CRLM have the lowest
complication and mortality rates, even after chemotherapy.38
ALPPS has expanded the treatment options for patients with
CLRM once deemed unresectable due to high tumor load and a small
FLR volume. Though recurrence rates appear higher, when compared
with patients with conventional liver resections, ALPPS is offering a
chance for cure for thosepatients,whootherwisewould haveno surgical
option. Robust long-term clinical and oncological outcome studies of
ALPPS forCRLMare, however, still lacking, but 3-yearoverall survival
of 50% and a disease-free survival rate of 13% at 3 years with quality of
life similar to the general population have been reported.40
Is ALPPS a Viable Option for Perihilar
Cholangiocarcinoma?
While the very first ALPPS procedure was performed in a
patient with PHC1, the international ALPPS registry counts only
11 patients with PHC with a 90 day-mortality rate of 27%. This
figure is consistent with an Italian multicenter study demonstrating a
high mortality rate in biliary tumors (10% after stage 1 and 30%
after stage 2).41 Most recently, biliary tumors and elevated serum
bilirubin (pre stage 2) were identified as predictors of futile outcome
after ALPPS.37 A comparison between ALPPS versus PVE and right
trisectionectomy for PHC using a matched case-control 1:1 from the
international ALPPS registry with data from the Amsterdam Medical
Center and theMemorial SloanKetteringCancerCenter suggested that
mortality was twice higher in the ALPPS group (48 vs. 24%).
Moreover, median survival was only 6 months after ALPPS and
29 months in the matched controls (P ¼ 0.05). In the ALPPS group,
4 patients died after stage 1, and another 10 patients after stage 2.42
There are, however, some shortcomings with the study in terms of
patient selection. Additionally, these results were obtained by conven-
tional ALPPS procedures (ie, complete transection) representing the
initial experience, (ie, learning curve with ALPPS in all centers). With
the recent modifications it is expected that morbidity and mortality
wouldbemuch lower. Themost attractive newvariant for PHCappears
to be partial parenchymal transection in combinationwith PVE instead
of portal vein ligation/transection, thus reducing post stage 1morbidity
by avoiding hilar dissection. PVE can be perfomed either during stage-
1 (Mini-ALPPS) or in the interstage course.32,33 These techniques
trigger a suitable FLR ina shortest possible time, thus avoiding the high
drop-out of the PVE alone. However, these variations have not been
convincingly tested in PHC, yet.
What Does ALPPS Offer Compared With
Conventional Two-stage Hepatectomy and to
Portal Vein Embolization?
So far, there is only 1 randomized controlled trial available
comparing ALPPS with TSH in patients with a standardized FLR less
than 30% (LIGRO Trial).43 This trial confirmed a significant higher
resection rate in ALPPS (main endpoint of the study) and comparable
surgical margins, peri-operative complications and mortality rates.
While the study offers a level 1 evidence for the previous observations
in the ALPPS registry, that is, higher rates of R0 resection, faster
regeneration with comparable perioperative mortality and morbidity,
we still need data regarding long-term outcome.43 Noteworthy, 35 of
49patients in the conventional 2-stage hepatectomygroupwere treated
with PVE. The study, therefore, clearly indicated that ALPPS offers
higher resection rates than PVE, importantly without higher rates of
complications. Also, ALPPS is effective after failure of PVE or PVL
(in 12 of 13 cases), known as rescue ALPPS.43
DISCUSSION
ALPPS is a recently developed procedure, first performed by
HJ Schlitt in Regensburg, Germany, with the inaugural small series
published by a fewGerman surgeons 5 years later.1 Despite increased
morbidity and mortality in the early phase, this novel procedure has
triggered major interest, and has rapidly climbed the IDEAL concept
of new surgical procedures or devices.44 Early after the inaugural
publication 1 accompanied by an editorial,2 an international registry3
was initiated with currently more than 1000 patients included. With
this tool, a collaborative effort from many centers all around the
world enabled us to improve patient selection, timing of stage 2, and
refinements of operative techniques, which allowed ALPPS morbid-
ity and mortality rates to match standard major liver resections. New
technical modifications, mostly minimizing the extensiveness of the
first-stage procedure, were associated with significant improvements
in safety, while preserving a high rate of curative resection.38 Stage 2
should be delayed or even abandoned in case of compromised
clinical status, complications, or abnormal liver function tests to
prevent postoperative mortality. Recent data from the only available
prospective RCT confirmed significant higher resection rates in
ALPPS and similar peri-operative complications and mortality
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figures compared with conventional 2-stage hepatectomy including
PVE.43 While the ALPPS technique is now becoming an established
concept, for example, for failure of PVE, several questions remain
unanswered, mostly in the L (long-term results) of the IDEAL
concept.44 The single RCT showed that ALPPS does not replace
other techniques, such as PVE for later hepatectomy, but it is central
in the toolkit of liver resection in the hands of experienced liver
surgeons. Attention should be put on important features to optimize
the ALPPS concept for specific situations in selecting not only proper
indications, but also regarding the adequate timing in the course of
the disease, for example, use of proper chemotherapy prior to any
surgery. Evidently, ALPPS is only 1 aspect of the overall oncologic
therapeutic concept of the patients.
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